The Translational Research Program (TRP) was formed to enhance the transfer of basic research findings to clinical usefulness. Applications are sought that propose novel approaches to the prevention, diagnosis, or treatment of hematological malignancies and related pre-malignant conditions. Proposals should be based on molecular, cellular, or integrated systems findings and be conceptually innovative. The application should have a clear plan for the eventual clinical translation of the studies proposed and the results expected. This feature will be an important consideration of the review process.
Deadline: October (Letter of Intent); January (full Application)
Value: Maximum Annual Direct Cost - $225,000; Maximum Annual Indirect Cost - $25,000; Maximum Total for 3 Years - $750,000; Indirect Costs are limited to 10% of the total costs requested in the application’s budget; In total, no more than forty percent (40%) of the direct costs may be requested for the salary and fringe benefit expenses of professional staff with a post-graduate degree (i.e., MD, PhD, DVM) regardless of function or role. This restriction does not apply to technical staff (lab assistants, nurses, etc.).
Eligibility: Applicants (Principal Investigator) must hold an M.D., Ph.D., or equivalent degree, and work in domestic or foreign non-profit organizations, such as universities, colleges, hospitals or laboratories. Applications may involve multiple such institutions and the Applicant (Principal Investigator) should have an independent research or academic position. Applicant (Principal Investigator) need not be U.S. citizens, and there are no restrictions on Applicant (Principal Investigator) age, race, gender or creed. Applications from non-academic facilities and the National Institute of Health are not eligible. Current TRP Grantees are eligible to reapply for an extension of similar research by submitting a Renewal Application (see Renewal Guidelines and Instructions). An Applicant (Principal Investigator) may only submit one application at a time.
Relevance: The proposed research should be clinically directed or clinically translatable in hematologic malignancies that is intended to develop innovative approaches to treatment, diagnosis, or prevention.
Fellowship Type: Graduate, Post-Graduate
Nomination: No, but strongly suggested to work with the Fellowships Office
Website: Leukemia and Lymphoma Society- translational research program
